Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.
Julie Jesson, PhD
Advertisement
Julie Jesson, PhD, is a researcher of epidemiology and biostatistics, focusing on adolescents’ global health and nutrition at the University of Toulouse.
Articles by Julie Jesson, PhD
A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5